PLUR
NASDAQPluri Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News25/Ratings0
Price$3.42+0.26 (+8.23%)
2026-01-162026-04-22
News · 26 weeks25-33%
2025-10-262026-04-19
Mix790d
- SEC Filings5(71%)
- Other1(14%)
- Offering1(14%)
Latest news
25 items- SECSEC Form DEFA14A filed by Pluri Inc.DEFA14A - Pluri Inc. (0001158780) (Filer)
- SECSEC Form DEF 14A filed by Pluri Inc.DEF 14A - Pluri Inc. (0001158780) (Filer)
- SECPluri Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Pluri Inc. (0001158780) (Filer)
- PRPluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private PlacementHAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. ("Pluri" or the "Company") (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that an entity beneficially owned by Alejandro Weinstein, Chairman of the Board and one of the Company's largest shareholders, has entered into a Securities Purchase Agreement with Pluri for an additional $2.5 million investment in the Company at a 30% premium to the market price on March 24, 2026. This additional investment follows Mr. Weinstein's prior $2.5 million investment announced in connection with his appointment as Chairman of the Board, and further
- SECPluri Inc. filed SEC Form 8-K: Other Events8-K - Pluri Inc. (0001158780) (Filer)
- PRPluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. PatentExpands patent protection across major global pharmaceutical markets, including the U.S., China and Asia-Pacific Enables scalable, automated manufacturing of diverse immune cell therapies using proprietary 3D expansion technology Strengthens positioning in China's growing cell therapy market and supports cross-border partnerships HAIFA, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. ("Pluri", the "Company", "we", "our" or "us") (Nasdaq and TASE: PLUR ), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announces that the China National Intellectual Property Administration (CNIPA) has gra
- SECSEC Form 10-Q filed by Pluri Inc.10-Q - Pluri Inc. (0001158780) (Filer)
- SECPluri Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Pluri Inc. (0001158780) (Filer)
- PRPluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich BiomaterialsHAIFA, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Pluri, Inc. ("Pluri", the "Company", "we" or "us") (Nasdaq, TASE: PLUR), a biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced the completion of the first phase of its program with Resbiomed Technologies OOD ("Resbiomed"), a European biotechnology company developing extracellular-matrix-based biomaterials and biologics for regenerative medicine. The program is being executed through Pluri's contract development and manufacturing division, PluriCDMO™. In June 2025, Pluri Biotech Ltd., a wholly owned subsidiary of the Company, and a provider of Contrac
- INSIDERDirector Manieu Alexandre Weinstein was granted 625,000 shares (SEC Form 4)4 - Pluri Inc. (0001158780) (Issuer)
- PRPluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing AchievedHAIFA, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Pluri, Inc. ("Pluri", the "Company", "we" or "us") (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell Ltd. ("Remedy Cell"), an innovative biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions. Under the ongoing collaboration Remedy Cell's personnel, along with Pluri's Contract Development and Manufacturing Organization ("CDMO") division (PluriCDMO™), have successfully completed the full imp
- SECPluri Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Other Events, Financial Statements and Exhibits8-K - Pluri Inc. (0001158780) (Filer)
- PRPluri Appoints Alejandro Weinstein as Chairman of the Board to Lead Strategic Shift and Unlock Value, Backed by Additional InvestmentWeinstein brings a global track record of transforming companies through value unlocking, and participation in over 20 M&A transactions and more than $5 billion in exits across healthcare, biotechnology, and nutrition.Weinstein's ownership is expected to increase to approximately 30% on an issued and outstanding basis, reflecting his conviction in Pluri's asset base, its valuation potential, and its long term strategy. HAIFA, Israel, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. ("Pluri" or the "Company") (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that Mr. Alejandro Weinstein, one of the C
- INSIDERDirector Manieu Alexandre Weinstein was granted 519 shares, increasing direct ownership by 5% to 10,769 units (SEC Form 4)4 - Pluri Inc. (0001158780) (Issuer)
- INSIDERDirector Ajchenbaum Eitan was granted 668 shares, increasing direct ownership by 6% to 12,353 units (SEC Form 4)4 - Pluri Inc. (0001158780) (Issuer)
- INSIDERChief Executive Officer Yanay Yaky was granted 6,588 shares, increasing direct ownership by 1% to 497,758 units (SEC Form 4)4 - Pluri Inc. (0001158780) (Issuer)
- INSIDERDirector Levi Rami Avraham was granted 653 shares, increasing direct ownership by 4% to 18,967 units (SEC Form 4)4 - Pluri Inc. (0001158780) (Issuer)
- INSIDERChief Financial Officer Zalts Liat was granted 3,660 shares, increasing direct ownership by 4% to 92,767 units (SEC Form 4)4 - Pluri Inc. (0001158780) (Issuer)
- INSIDERDirector Shemesh-Rasmussen Maital was granted 699 shares, increasing direct ownership by 4% to 19,144 units (SEC Form 4)4 - Pluri Inc. (0001158780) (Issuer)
- INSIDERDirector Aberman Zami was granted 346 shares, increasing direct ownership by 0.24% to 144,212 units (SEC Form 4)4 - Pluri Inc. (0001158780) (Issuer)
- INSIDERDirector Manieu Alexandre Weinstein was granted 10,250 shares, exercised 1,002,169 shares at a strike of $0.00 and bought $2,086,956 worth of shares (452,702 units at $4.61) (SEC Form 4)4 - Pluri Inc. (0001158780) (Issuer)
- INSIDERDirector Ajchenbaum Eitan was granted 11,685 shares (SEC Form 4)4 - Pluri Inc. (0001158780) (Issuer)
- SECSEC Form 10-Q filed by Pluri Inc.10-Q - Pluri Inc. (0001158780) (Filer)
- PRPluri Partners with Miss Universe Skincare Introducing Exosome-Enhanced Regenerative SkincarePluri launches wholly-owned health and aesthetics subsidiary Cellav- leveraging Pluri's proprietary 3D cell expansion platform to deliver advanced exosome-based technologies for medical aestheticsThe partnership with Miss Universe Skincare, a global beauty and wellness entity, establishes a global distribution channel in the beauty market, which is projected to reach $194.05 billion by 2032 HAIFA, Israel, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. ("Pluri", the "Company", "we", "our" or "us") (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announces the launch of Cell
- PRLeading Global Players Back and Fund Pluri's Cell-Based Food and Agriculture CollaborationsPluri entered strategic collaborations across Asia, Europe and the United States ("U.S.") to transform food and agriculture production via its subsidiaries' advanced cell expansion technologies Pluri's subsidiaries Ever After Foods, Kokomodo, and Coffeesai will potentially expand market presence in cultivated meat, cultivated cacao, and cell-based coffee industries amid growing global demand for scalable, sustainable solutionsEach collaboration is anchored by a minimum-viable-product ("MVP"), funded by leading global players entering an agreement. This structure is aimed at bringing the parties' substantial commitment and trust in the collaboration's innovative potential HAIFA, Israel, Nov.